JP5651233B2 - 簡易なカプセル・ベースの吸入器 - Google Patents
簡易なカプセル・ベースの吸入器 Download PDFInfo
- Publication number
- JP5651233B2 JP5651233B2 JP2013506742A JP2013506742A JP5651233B2 JP 5651233 B2 JP5651233 B2 JP 5651233B2 JP 2013506742 A JP2013506742 A JP 2013506742A JP 2013506742 A JP2013506742 A JP 2013506742A JP 5651233 B2 JP5651233 B2 JP 5651233B2
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- inhaler
- tray
- opening
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims description 261
- 239000000843 powder Substances 0.000 claims description 77
- 238000005520 cutting process Methods 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 229940112141 dry powder inhaler Drugs 0.000 claims description 19
- 238000009825 accumulation Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 238000000465 moulding Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 description 17
- 238000013461 design Methods 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 229920003023 plastic Polymers 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 6
- 239000000428 dust Substances 0.000 description 6
- -1 disperses Substances 0.000 description 5
- 239000010419 fine particle Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 4
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 4
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 238000005553 drilling Methods 0.000 description 4
- 229960002848 formoterol Drugs 0.000 description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 4
- 238000001746 injection moulding Methods 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000004734 Polyphenylene sulfide Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000003434 inspiratory effect Effects 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 229920001707 polybutylene terephthalate Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000069 polyphenylene sulfide Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000106 Liquid crystal polymer Polymers 0.000 description 2
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
- 229940110309 tiotropium Drugs 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012504 compendial method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108010067396 dornase alfa Chemical class 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229950004244 laninamivir Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Chemical class 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0038—Cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/004—Details of the piercing or cutting means with fixed piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0063—Storages for pre-packed dosages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
トレイ110は、チャンバ121を露出させるように吸入器本体100から引き出され、新しい密封されたカプセル123がチャンバ121内に装填される。次いで、レール104がレール・ストップ124と係合するまで、トレイ110は、吸入器本体100における開口部102内へ確実に戻るようにスライドされる。トレイが開口部102内に移動すると、ブレード150、151は、トレイ内の各スロット(溝)155に沿って移動し、カプセルの頂部および底部に切れ目を入れる。
本発明における吸入器の実施形態は、その空気力学的プロファイル(外形、輪郭)並びにその散剤投与送達を判定するために、試験された。1カプセル当り18μgの用量(投与量)のチオトロピウム(tiotropium)を含む実験的な乳糖ベースの混合物が調剤されて、吸入器の分散および同伴(entrainment:取り込み)効力が判定された。
Claims (15)
- 肺または鼻への投与に適したドライ・パウダー吸入器であって、
前記ドライ・パウダー吸入器は、吸入器本体と、薬剤を含むカプセルを支持するよう内部に形成されたカプセル・チャンバを有するカプセル・トレイとを含み、
前記吸入器本体は、
対向する上壁と下壁の間に画定され内部に形成されていて、少なくとも1つの端部開口を有する吸入器本体開口部であって、前記少なくとも1つの端部開口によって前記カプセル・トレイが前記吸入器本体開口部に係合され得るよう構成された、吸入器本体開口部と、
前記上壁を貫通して伸び、前記吸入器本体の前記開口部で開口し、他端部の吸入チューブで開口する吸入路と、
前記上壁および前記下壁に設けられたカット手段と、
を含み、
前記カプセル・トレイは、前記開口端部を通って第1の位置と第2の位置の間で前記開口部に可動的に係合可能であり、
前記第1の位置は、カプセルを前記カプセル・チャンバに装填し前記カプセル・チャンバから取り出すことを可能にするよう、前記カプセル・トレイが前記開口部から引き出された位置であり、
前記第2の位置は、前記カプセル内に含まれる薬剤を前記吸入路を通して吸入することを可能にするよう、前記カプセル・チャンバが前記吸入器本体の前記上壁中の前記吸入路および前記下壁上の入口と整列する位置であり、
前記カット手段は、前記カプセル・トレイが前記第1の位置から前記第2の位置に動かされると、前記カプセルの頂部および底部に食い込んで、前記カプセルの頂部および底部を切って各開口が形成されるようにし、
特徴として、
前記カット手段は、前記吸入器本体と一体化され、同じ材料で形成され、同じ1つの工程で製造されて、前記吸入器が2つの操作部品だけで形成されるものである、ドライ・パウダー吸入器。 - 前記本体および前記カット手段は、単一の成型工程で形成されるものである、請求項1に記載のドライ・パウダー吸入器。
- 前記カット手段がブレードである、請求項1または2に記載のドライ・パウダー吸入器。
- 各カット手段は、前記カプセル・トレイの前記第1の位置と前記第2の位置の間の移動方向に実質的に垂直な2つのカット部分を有し、
前記2つのカット部分は、使用中に、前記カプセル・トレイがその第1の位置からその第2の位置へ移動すると前記2つのカット部分の一方が前記カプセルに食い込み、前記カプセル・トレイが前記第2の位置から前記第1の位置へ移動すると前記2つのカット部分の他方が前記カプセルに食い込むよう、互いに反対方向を向くものである、
請求項1乃至3のいずれかに記載のドライ・パウダー吸入器。 - 前記カット手段がブレードであり、前記カット部分が前記ブレードの刃先である、請求項4に記載のドライ・パウダー吸入器。
- 各ブレードが菱形の断面を有する、請求項5に記載のドライ・パウダー吸入器。
- 各ブレードが2つの湾曲のある断面を有する、請求項5に記載のドライ・パウダー吸入器。
- 各ブレードがその断面の中心を横切る任意の軸について対称である、請求項5乃至7のいずれかに記載のドライ・パウダー吸入器。
- 各カット手段は、その各カット部分が、前記各カット手段が対応付けて設けられた前記本体の一方の壁から前記本体の他方の壁に向けて実質的に垂直に伸びるよう構成されている、請求項4乃至8のいずれかに記載のドライ・パウダー吸入器。
- 前記カプセル・トレイは、前記吸入器本体開口部に前記カプセル・トレイを挿入しおよび前記吸入器本体開口部から取り出す期間中に、前記吸入器本体の前記上壁および前記下壁にそれぞれ接触または隣接する互いに逆向きの上壁および下壁を有し、この上壁および下壁の少なくとも一方の外面は、前記吸入器本体開口部の前記壁上での粉末の蓄積を減少させるよう作用する起伏ある表面を有するものである、請求項1乃至9のいずれかに記載のドライ・パウダー吸入器。
- 前記カプセル・トレイの前記両壁の外面に、起伏のある仕上げが存在する、請求項10に記載のドライ・パウダー吸入器。
- 前記起伏ある表面または各起伏ある表面は、リッジ状、溝状または半球状の突出部を有するものである、請求項10または11に記載のドライ・パウダー吸入器。
- 前記起伏ある表面または各起伏ある表面は、シェブロン状パターンを有するものである、請求項12に記載のドライ・パウダー吸入器。
- 前記起伏ある表面または各起伏ある表面は、前記カプセル・トレイの端縁に対して垂直な複数の平行なリッジを有するものである、請求項12に記載のドライ・パウダー吸入器。
- 前記起伏ある表面または各起伏ある表面は、前記カプセル・トレイの端縁に対して傾斜した複数の平行なリッジを有するものである、請求項12に記載のドライ・パウダー吸入器。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT105065A PT105065B (pt) | 2010-04-26 | 2010-04-26 | Um inalador simples de cápsulas |
PTPT105065 | 2010-04-26 | ||
PCT/GB2011/050760 WO2011135327A1 (en) | 2010-04-26 | 2011-04-18 | A simple capsule-based inhaler |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013524976A JP2013524976A (ja) | 2013-06-20 |
JP5651233B2 true JP5651233B2 (ja) | 2015-01-07 |
Family
ID=44276250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013506742A Active JP5651233B2 (ja) | 2010-04-26 | 2011-04-18 | 簡易なカプセル・ベースの吸入器 |
Country Status (26)
Country | Link |
---|---|
US (1) | US8677992B2 (ja) |
EP (1) | EP2536460B1 (ja) |
JP (1) | JP5651233B2 (ja) |
KR (1) | KR101266884B1 (ja) |
CN (1) | CN102933244B (ja) |
AR (1) | AR080968A1 (ja) |
AU (1) | AU2011247073B2 (ja) |
BR (1) | BR112012027254A8 (ja) |
CA (1) | CA2791149C (ja) |
CL (1) | CL2012002970A1 (ja) |
CO (1) | CO6561767A2 (ja) |
DK (1) | DK2536460T3 (ja) |
ES (1) | ES2431832T3 (ja) |
HK (1) | HK1174863A1 (ja) |
HR (1) | HRP20130923T1 (ja) |
IL (1) | IL221662A (ja) |
MX (1) | MX2012012464A (ja) |
MY (1) | MY160369A (ja) |
NZ (1) | NZ601830A (ja) |
PL (1) | PL2536460T3 (ja) |
PT (1) | PT105065B (ja) |
RU (1) | RU2536251C2 (ja) |
SG (1) | SG183307A1 (ja) |
TW (1) | TWI539980B (ja) |
WO (1) | WO2011135327A1 (ja) |
ZA (1) | ZA201206059B (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
CA2479751C (en) | 2002-03-20 | 2008-06-03 | Trent Poole | Inhalation apparatus |
DE602005024413D1 (de) | 2004-08-20 | 2010-12-09 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
RU2390325C2 (ru) | 2005-09-14 | 2010-05-27 | Маннкайнд Корпорейшн | Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц |
WO2007098500A2 (en) | 2006-02-22 | 2007-08-30 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
CN101827626B (zh) | 2008-06-13 | 2015-03-18 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2676695A3 (en) | 2009-03-11 | 2017-03-01 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US8734845B2 (en) | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
BR112012033060A2 (pt) | 2010-06-21 | 2018-02-27 | Mannkind Corp | métodos de sistema de liberação de fármaco em pó seco |
SG194034A1 (en) | 2011-04-01 | 2013-11-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
PT106094A (pt) * | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | Administração por inalação de formulações com dose elevada |
WO2013176635A1 (en) * | 2012-05-25 | 2013-11-28 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhaler device having an improved guide gear |
BR112015000529B1 (pt) | 2012-07-12 | 2022-01-11 | Mannkind Corporation | Inalador de pó seco |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
GB201301192D0 (en) | 2013-01-23 | 2013-03-06 | Vectura Delivery Devices Ltd | A blister piercing element for a dry powder inhaler |
EP2968161A4 (en) * | 2013-03-13 | 2016-10-26 | Forest Lab Holdings Ltd | MICRONIZED PHARMACEUTICAL COMPOSITIONS |
KR102499439B1 (ko) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
PT106856A (pt) * | 2013-03-26 | 2014-09-26 | Beyondevices Lda | Sistema e processo de difusão de fármaco em pó a partir de uma cápsula e inalador compreendendo tal sistema |
MX2020009878A (es) | 2013-07-18 | 2022-07-27 | Mannkind Corp | Composiciones farmaceuticas en polvo seco estables al calor y metodos. |
JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
PT107627B (pt) | 2014-04-29 | 2017-03-08 | Hovione Farmaciência S A | Inalador de cápsulas com dobradiça |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
KR101494701B1 (ko) * | 2014-10-22 | 2015-02-26 | (주)메가메디칼 | 간접적으로 약액을 분무화하는 네블라이저 |
CN106031810A (zh) * | 2015-03-13 | 2016-10-19 | 丁要武 | 吸粉器及连接于该吸粉器的吸粉器本体上的药匣组件 |
RU2715687C2 (ru) * | 2015-04-15 | 2020-03-02 | Филип Моррис Продактс С.А. | Порошковый ингалятор и способ его применения |
PT108426B (pt) * | 2015-04-30 | 2017-07-24 | Hovione Farmaciência S A | Inalador de pó para administração de doses elevadas de fármacos |
RU2601493C1 (ru) * | 2015-07-15 | 2016-11-10 | Виктор Альбертович Пилюш | Трехзвенный роторно-кулачковый механизм |
DK3284499T3 (da) | 2016-08-15 | 2019-09-02 | Tiefenbacher Alfred E Gmbh & Co Kg | Tørpulverinhalator med reproducerbar strømmodstand |
AU2018275561A1 (en) | 2017-05-31 | 2019-12-12 | Virginia Commonwealth University | Devices, systems, and methods for dry powder therapies |
US20220023553A1 (en) | 2018-12-04 | 2022-01-27 | Hovione Technology Ltd | Large dose disposable inhaler and method of simple filling |
CN113117193B (zh) * | 2021-04-20 | 2024-02-06 | 苏州新劢德医疗器械科技有限公司 | 吸入装置 |
WO2024100652A1 (en) | 2022-11-07 | 2024-05-16 | Kritzman Kadron Amnon | High performance dry powder inhaler |
GB2626332A (en) | 2023-01-18 | 2024-07-24 | Merxin Ltd | Inhalation device |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7028A (en) * | 1850-01-15 | Spindle and bobbin foe spinning | ||
FR21844E (fr) | 1919-11-25 | 1921-03-30 | Edmond Louis Octave Denis | Peseur à alimentation continue |
GB1182779A (en) | 1966-09-17 | 1970-03-04 | Fisons Pharmaceuticals Ltd | Inhalation Device |
DE3345722A1 (de) * | 1983-12-17 | 1985-06-27 | Boehringer Ingelheim KG, 6507 Ingelheim | Inhalator |
DE4142238A1 (de) * | 1991-12-20 | 1993-06-24 | Boehringer Ingelheim Kg | Pulverinhalator mit pulvertraeger aus regelmaessigen mikrostrukturen |
PT101450B (pt) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | Novo dispositivo para inalacao |
DK0995457T3 (da) | 1995-12-07 | 2004-08-16 | Jago Res Ag | Mundstykke til inhalator til flere dosisvise afgivelser af farmakologisk törpulver |
US6470884B2 (en) | 1996-01-29 | 2002-10-29 | Aventis Pharma Limited | Capsule opening arrangement for use in a powder inhaler |
US5871010A (en) * | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
EP1350532B1 (en) * | 1997-01-30 | 2008-04-09 | Hitachi, Ltd. | Capsule type powder Inhaler |
JP2004501711A (ja) * | 2000-05-16 | 2004-01-22 | タウト インコーポレイテッド | トロカールアセンブリ用穿刺用先端部 |
SE517229C2 (sv) * | 2000-09-25 | 2002-05-14 | Microdrug Ag | Kontinuerlig inhalator för torrt pulver |
EP1245243B1 (en) | 2001-03-28 | 2006-05-31 | Ivo Pera | Pen-shaped inhaling device for dispersing powdered medicaments through the respiratory tract |
US6766799B2 (en) * | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
JP3975327B2 (ja) | 2001-11-19 | 2007-09-12 | 株式会社 バイオアクティス | 鼻腔用粉状薬剤施薬装置 |
ITMI20020078A1 (it) | 2002-01-16 | 2003-07-16 | Fabrizio Niccolai | Dispositivo utilizzabile nel tratamento di affezzioni delle vie respiratorie |
ITMO20020297A1 (it) * | 2002-10-16 | 2004-04-17 | Roberto Oliva | Inalatore per preparati monodose in capsule. |
PL1603615T3 (pl) | 2003-03-20 | 2009-01-30 | Galephar M/F | Ulepszony układ inhalatora suchego proszku |
US7451761B2 (en) * | 2003-10-27 | 2008-11-18 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
SE528190C2 (sv) * | 2004-06-07 | 2006-09-19 | Mederio Ag | Inhalator |
GB0507711D0 (en) * | 2005-04-15 | 2005-05-25 | Vectura Group Plc | Improved blister piercing |
DE102006006647B3 (de) | 2006-02-14 | 2007-01-18 | Braunform Gmbh | Vorrichtung zum Inhalieren eines in einer Kapsel sich befindenden Pulvers |
DE102006010089A1 (de) | 2006-02-24 | 2007-10-18 | Aha-Kunststofftechnik Gmbh | Trockenpulver-Inhalator |
US7832399B2 (en) * | 2006-03-10 | 2010-11-16 | One Dose, Llc | Medication inhaler |
EP1844805A1 (de) | 2006-04-13 | 2007-10-17 | Boehringer Ingelheim Pharma GmbH & Co.KG | Inhalator |
PT103481B (pt) * | 2006-05-16 | 2008-08-01 | Hovione Farmaciencia S A | Inalador de uso simples e método de inalação |
US7806117B2 (en) | 2006-06-07 | 2010-10-05 | Shin Nippon Biomedical Laboratories, Ltd. | Peroral powder delivery device |
US8522775B2 (en) | 2006-06-16 | 2013-09-03 | Cipla Limited | Dry powder inhaler |
KR101501784B1 (ko) * | 2006-10-25 | 2015-03-11 | 노파르티스 아게 | 분말 분산 장치, 이 장치를 제작 및 사용하는 방법, 및 장치 및 기타 기기 상에서 사용될 수 있는 구성요소 |
DE102007036411A1 (de) | 2007-07-20 | 2009-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverinhalator |
WO2009117112A2 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Powder dispersion apparatus, method of making and using the apparatus, components that can be used on the apparatus and other devices, and various active agents |
TR200803525A2 (tr) | 2008-05-16 | 2009-12-21 | Bi̇lgi̇ç Mahmut | Toz ilaç soluma cihazı. |
-
2010
- 2010-04-26 PT PT105065A patent/PT105065B/pt active IP Right Grant
-
2011
- 2011-04-18 KR KR1020127026794A patent/KR101266884B1/ko active IP Right Grant
- 2011-04-18 MX MX2012012464A patent/MX2012012464A/es active IP Right Grant
- 2011-04-18 MY MYPI2012700744A patent/MY160369A/en unknown
- 2011-04-18 CN CN201180021233.4A patent/CN102933244B/zh active Active
- 2011-04-18 CA CA2791149A patent/CA2791149C/en not_active Expired - Fee Related
- 2011-04-18 ES ES11716635T patent/ES2431832T3/es active Active
- 2011-04-18 SG SG2012060042A patent/SG183307A1/en unknown
- 2011-04-18 JP JP2013506742A patent/JP5651233B2/ja active Active
- 2011-04-18 WO PCT/GB2011/050760 patent/WO2011135327A1/en active Application Filing
- 2011-04-18 RU RU2012141640/15A patent/RU2536251C2/ru not_active IP Right Cessation
- 2011-04-18 AU AU2011247073A patent/AU2011247073B2/en not_active Ceased
- 2011-04-18 DK DK11716635.5T patent/DK2536460T3/da active
- 2011-04-18 NZ NZ601830A patent/NZ601830A/xx not_active IP Right Cessation
- 2011-04-18 PL PL11716635T patent/PL2536460T3/pl unknown
- 2011-04-18 EP EP11716635.5A patent/EP2536460B1/en active Active
- 2011-04-18 BR BR112012027254A patent/BR112012027254A8/pt not_active Application Discontinuation
- 2011-04-26 AR ARP110101431A patent/AR080968A1/es active IP Right Grant
- 2011-04-26 US US13/094,108 patent/US8677992B2/en active Active
- 2011-04-26 TW TW100114493A patent/TWI539980B/zh active
-
2012
- 2012-08-13 ZA ZA2012/06059A patent/ZA201206059B/en unknown
- 2012-08-27 IL IL221662A patent/IL221662A/en active IP Right Grant
- 2012-10-24 CL CL2012002970A patent/CL2012002970A1/es unknown
- 2012-10-25 CO CO12191328A patent/CO6561767A2/es active IP Right Grant
-
2013
- 2013-02-15 HK HK13101979.8A patent/HK1174863A1/xx not_active IP Right Cessation
- 2013-09-30 HR HRP20130923AT patent/HRP20130923T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5651233B2 (ja) | 簡易なカプセル・ベースの吸入器 | |
JP4395642B2 (ja) | 簡易吸入器 | |
US5787881A (en) | Inhalation device | |
CA2444129C (en) | Inhalation device and method | |
JP3790423B2 (ja) | 薬剤のデリバリの引き金となる吸入活性化流れ分割手段を有する乾燥粉末薬剤吸入器 | |
KR20100103813A (ko) | 에어로졸화가능 제약 제제의 저장기 | |
JPH04227269A (ja) | 粉末薬物の投与器具 | |
TWI590846B (zh) | 可吸入式藥劑 | |
WO2009091780A2 (en) | Device for inhaling powdered medicaments | |
EP2617451B1 (en) | Drug delivery assembly, and single dose inhaler for dry powder drug delivery having such assembly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141028 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5651233 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |